Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant epirubicin + docetaxel followed by carboplatin + docetaxel in primary breast cancer
2005-003601-93Phase 2Completed
- Sponsor
- Asklepios Klinik Weißenfels
- Start
- Dec 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, epirubicin and carboplatin in breast cancer, sponsored by Asklepios Klinik Weißenfels. Primary endpoint: Pathological complete response. Started Dec 2005; status: completed.
02
Drugs
docetaxelepirubicincarboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-003601-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003601-93.